<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250376</url>
  </required_header>
  <id_info>
    <org_study_id>32222-1</org_study_id>
    <nct_id>NCT04250376</nct_id>
  </id_info>
  <brief_title>The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias</brief_title>
  <official_title>The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurological Associates of West Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurological Associates of West Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open label study is to evaluate longer term tolerability and early
      efficacy of transcranial ultrasound in the treatment of patients with mild cognitive
      impairment or dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study is designed as an open label study of patients with mild cognitive
      impairment (MCI) or dementia to evaluate longer term tolerability and early efficacy of
      transcranial ultrasound treatment.

      Baseline and outcome measures in this study utilize validated tests that are appropriate for
      repeated measures which are not affected by practice effects. For patients with amnestic
      predominant cognitive change, the target will be the mesial temporal lobe through a trans
      temporal scalp window. Targeting will include reference to scalp fiducials based on the
      obtained MRI and Transcranial Doppler (TCD) waveform confirmation will be obtained because of
      the ability of TCD to record Doppler signal from the posterior cerebral artery that runs
      medial to the mesial temporal lobe.

      On the day of the ultrasound appointment, patients will undergo ten to thirty minutes of
      transcranial ultrasound treatment. The sonification device will be aimed at the hippocampus
      or the putamen and substantia nigra, depending on the predetermined condition. Targeting will
      include reference to scalp fiducials based on the obtained MRI; confirmation of target
      accuracy will either be obtained by Doppler waveform confirmation or optical tracking
      technology which co-registers patient neuroimaging with real space. Patients will undergo 8
      total sessions of focused ultrasound. Patients will be evaluated at baseline and upon final
      ultrasound treatment using the same measures obtained upon entry. Safety and any adverse
      events will be monitored closely.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quick Dementia Rating Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>The Quick Dementia Rating Scale (QDRS) is an interview-based tool administered by study officials to participants' caregivers used to obtain observations from a consistent source. The QDRS form consists of 10 categorical questions (5 cognitive, 5 functional), each with 5 detailed options depicting the level of impairment as either 0 (normal), 0.5 (mild/inconsistent impairment), 1 (mild/consistent impairment), 2 (moderate impairment), or 3 (severe impairment). Based on the conversion table outlined in Dr. James Galvin's research (2015), total QDRS scores were converted to Clinical Dementia Rating (CDR) scale levels ranging from 0 (normal aging), 0.5 (mild cognitive impairment), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repeatable Battery Assessment for Neuropsychological Status (RBANS)</measure>
    <time_frame>Baseline</time_frame>
    <description>RBANS assesses immediate memory, visuospatial skill, language, attention, and delayed memory. Patient performance on each subscale immediate memory, language, attention, visuospatial, and delayed memory are scored relative to validated norms for same-aged peers. A change of 8+ points in the Total Scale score, 11+ points in the Immediate Memory score, 9+ points in the Language score, 4+ points on the Attention score, 14+ points is considered significant for the Visuospatial score, and 10+ points for the Delayed Memory score are considered significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeatable Battery Assessment for Neuropsychological Status (RBANS)</measure>
    <time_frame>After final ultrasound (8 weeks from baseline)</time_frame>
    <description>RBANS assesses immediate memory, visuospatial skill, language, attention, and delayed memory. Patient performance on each subscale immediate memory, language, attention, visuospatial, and delayed memory are scored relative to validated norms for same-aged peers. A change of 8+ points in the Total Scale score, 11+ points in the Immediate Memory score, 9+ points in the Language score, 4+ points on the Attention score, 14+ points is considered significant for the Visuospatial score, and 10+ points for the Delayed Memory score are considered significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline</time_frame>
    <description>The MoCA evaluates frontal-executive functions (e.g., verbal abstraction and mental calculation), language (e.g., confrontation naming, phonemic fluency), orientation (e.g., person, place, date, day of the week, and time), visuospatial construction (e.g., simple figure copy), divided visual attention, and immediate and delayed memory of unstructured information. MoCA scores range from 0-30 possible points; 26 or greater is considered to reflect normal cognitive status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>After final ultrasound (8 weeks from baseline)</time_frame>
    <description>The MoCA evaluates frontal-executive functions (e.g., verbal abstraction and mental calculation), language (e.g., confrontation naming, phonemic fluency), orientation (e.g., person, place, date, day of the week, and time), visuospatial construction (e.g., simple figure copy), divided visual attention, and immediate and delayed memory of unstructured information. MoCA scores range from 0-30 possible points; 26 or greater is considered to reflect normal cognitive status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Dementia Rating Scale (QDRS)</measure>
    <time_frame>After final ultrasound (8 weeks from baseline)</time_frame>
    <description>The Quick Dementia Rating Scale (QDRS) is an interview-based tool administered by study officials to participants' caregivers used to obtain observations from a consistent source. The QDRS form consists of 10 categorical questions (5 cognitive, 5 functional), each with 5 detailed options depicting the level of impairment as either 0 (normal), 0.5 (mild/inconsistent impairment), 1 (mild/consistent impairment), 2 (moderate impairment), or 3 (severe impairment). Based on the conversion table outlined in Dr. James Galvin's research (2015), total QDRS scores were converted to Clinical Dementia Rating (CDR) scale levels ranging from 0 (normal aging), 0.5 (mild cognitive impairment), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Mild Dementia</condition>
  <condition>Parkinson Disease</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled will receive transcranial focused ultrasound. Target location is dependent on patient condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Focused Transcranial Ultrasound</intervention_name>
    <description>The FDA has determined the power intensity limits that are safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion (for example for hippocampal targets, there will be a delayed recall memory test).</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CDR stage of at least 0.5 (mild cognitive impairment)

          -  At least one pathognomic imaging biomarker of a neurodegenerative process.

        Exclusion Criteria:

          -  Cognitive decline clearly related to an acute illness

          -  Subjects unable to give informed consent

          -  Subjects with scalp rash or open wounds on the scalp (for example from treatment of
             squamous cell cancer)

          -  Advanced terminal illness

          -  Advanced kidney, pulmonary, cardiac or liver failure

          -  Subjects who would not be able to lay down without excessive movement in a calm
             environment sufficiently long enough to be able to achieve sleep

          -  Subjects with major depressive disorder

          -  Subjects with vascular causes of dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>93 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon E Jordan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Management Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurological Associates of West LA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burgess A, Dubey S, Yeung S, Hough O, Eterman N, Aubert I, Hynynen K. Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology. 2014 Dec;273(3):736-45. doi: 10.1148/radiol.14140245. Epub 2014 Sep 15.</citation>
    <PMID>25222068</PMID>
  </reference>
  <reference>
    <citation>Chen K, Lu Z, Xin YC, Cai Y, Chen Y, Pan SM. Alpha-2 agonists for long-term sedation during mechanical ventilation in critically ill patients. Cochrane Database Syst Rev. 2015 Jan 6;1:CD010269. doi: 10.1002/14651858.CD010269.pub2. Review.</citation>
    <PMID>25879090</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald PJ. Is elevated norepinephrine an etiological factor in some cases of Alzheimer's disease? Curr Alzheimer Res. 2010 Sep;7(6):506-16. Review.</citation>
    <PMID>20626335</PMID>
  </reference>
  <reference>
    <citation>Nir Y, Staba RJ, Andrillon T, Vyazovskiy VV, Cirelli C, Fried I, Tononi G. Regional slow waves and spindles in human sleep. Neuron. 2011 Apr 14;70(1):153-69. doi: 10.1016/j.neuron.2011.02.043.</citation>
    <PMID>21482364</PMID>
  </reference>
  <reference>
    <citation>Fucke T, Suchanek D, Nawrot MP, Seamari Y, Heck DH, Aertsen A, Boucsein C. Stereotypical spatiotemporal activity patterns during slow-wave activity in the neocortex. J Neurophysiol. 2011 Dec;106(6):3035-44. doi: 10.1152/jn.00811.2010. Epub 2011 Aug 17.</citation>
    <PMID>21849616</PMID>
  </reference>
  <reference>
    <citation>Iliff JJ, Goldman SA, Nedergaard M. Implications of the discovery of brain lymphatic pathways. Lancet Neurol. 2015 Oct;14(10):977-9. doi: 10.1016/S1474-4422(15)00221-5.</citation>
    <PMID>26376966</PMID>
  </reference>
  <reference>
    <citation>Jagust W. Is amyloid-β harmful to the brain? Insights from human imaging studies. Brain. 2016 Jan;139(Pt 1):23-30. doi: 10.1093/brain/awv326. Epub 2015 Nov 27. Review.</citation>
    <PMID>26614753</PMID>
  </reference>
  <reference>
    <citation>Jordão JF, Thévenot E, Markham-Coultes K, Scarcelli T, Weng YQ, Xhima K, O'Reilly M, Huang Y, McLaurin J, Hynynen K, Aubert I. Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol. 2013 Oct;248:16-29. doi: 10.1016/j.expneurol.2013.05.008. Epub 2013 May 21.</citation>
    <PMID>23707300</PMID>
  </reference>
  <reference>
    <citation>Kim H, Chiu A, Lee SD, Fischer K, Yoo SS. Focused ultrasound-mediated non-invasive brain stimulation: examination of sonication parameters. Brain Stimul. 2014 Sep-Oct;7(5):748-56. doi: 10.1016/j.brs.2014.06.011. Epub 2014 Jul 2.</citation>
    <PMID>25088462</PMID>
  </reference>
  <reference>
    <citation>Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, Liew JA, Plog BA, Ding F, Deane R, Nedergaard M. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014 Dec;76(6):845-61. doi: 10.1002/ana.24271. Epub 2014 Sep 26.</citation>
    <PMID>25204284</PMID>
  </reference>
  <reference>
    <citation>Lavialle M, Aumann G, Anlauf E, Pröls F, Arpin M, Derouiche A. Structural plasticity of perisynaptic astrocyte processes involves ezrin and metabotropic glutamate receptors. Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12915-9. doi: 10.1073/pnas.1100957108. Epub 2011 Jul 13.</citation>
    <PMID>21753079</PMID>
  </reference>
  <reference>
    <citation>Lee W, Kim H, Jung Y, Song IU, Chung YA, Yoo SS. Image-guided transcranial focused ultrasound stimulates human primary somatosensory cortex. Sci Rep. 2015 Mar 4;5:8743. doi: 10.1038/srep08743.</citation>
    <PMID>25735418</PMID>
  </reference>
  <reference>
    <citation>Leinenga G, Götz J. Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model. Sci Transl Med. 2015 Mar 11;7(278):278ra33. doi: 10.1126/scitranslmed.aaa2512.</citation>
    <PMID>25761889</PMID>
  </reference>
  <reference>
    <citation>Leshchyns'ka I, Liew HT, Shepherd C, Halliday GM, Stevens CH, Ke YD, Ittner LM, Sytnyk V. Aβ-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease. Nat Commun. 2015 Nov 27;6:8836. doi: 10.1038/ncomms9836.</citation>
    <PMID>26611261</PMID>
  </reference>
  <reference>
    <citation>Lim AS, Ellison BA, Wang JL, Yu L, Schneider JA, Buchman AS, Bennett DA, Saper CB. Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer's disease. Brain. 2014 Oct;137(Pt 10):2847-61. doi: 10.1093/brain/awu222. Epub 2014 Aug 20.</citation>
    <PMID>25142380</PMID>
  </reference>
  <reference>
    <citation>Lin GG, Scott JG. Investigations of the constitutive overexpression of CYP6D1 in the permethrin resistantLPR strain of house fly (Musca domestica). Pestic Biochem Physiol. 2011 Jun;100(2):130-134.</citation>
    <PMID>21765560</PMID>
  </reference>
  <reference>
    <citation>Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin JM, Ancoli-Israel S, Jagust WJ, Walker MP. β-amyloid disrupts human NREM slow waves and related hippocampus-dependent memory consolidation. Nat Neurosci. 2015 Jul;18(7):1051-7. doi: 10.1038/nn.4035. Epub 2015 Jun 1.</citation>
    <PMID>26030850</PMID>
  </reference>
  <reference>
    <citation>O'Donnell J, Ding F, Nedergaard M. Distinct functional states of astrocytes during sleep and wakefulness: Is norepinephrine the master regulator? Curr Sleep Med Rep. 2015 Mar;1(1):1-8. Epub 2015 Jan 29.</citation>
    <PMID>26618103</PMID>
  </reference>
  <reference>
    <citation>Ricci S, Dinia L, Del Sette M, Anzola P, Mazzoli T, Cenciarelli S, Gandolfo C. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008348. doi: 10.1002/14651858.CD008348.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;10:CD008348.</citation>
    <PMID>22696378</PMID>
  </reference>
  <reference>
    <citation>Scarcelli T, Jordão JF, O'Reilly MA, Ellens N, Hynynen K, Aubert I. Stimulation of hippocampal neurogenesis by transcranial focused ultrasound and microbubbles in adult mice. Brain Stimul. 2014 Mar-Apr;7(2):304-7. doi: 10.1016/j.brs.2013.12.012. Epub 2014 Jan 28.</citation>
    <PMID>24629831</PMID>
  </reference>
  <reference>
    <citation>Schlesinger D, Benedict S, Diederich C, Gedroyc W, Klibanov A, Larner J. MR-guided focused ultrasound surgery, present and future. Med Phys. 2013 Aug;40(8):080901. doi: 10.1118/1.4811136. Review.</citation>
    <PMID>23927296</PMID>
  </reference>
  <reference>
    <citation>Seitz DP, Reimer CL, Siddiqui N. A review of epidemiological evidence for general anesthesia as a risk factor for Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:122-7. doi: 10.1016/j.pnpbp.2012.06.022. Epub 2012 Jul 4. Review.</citation>
    <PMID>22771690</PMID>
  </reference>
  <reference>
    <citation>Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Update in: Nature. 2017 Jun 21;546(7659):564.</citation>
    <PMID>27582220</PMID>
  </reference>
  <reference>
    <citation>Shteamer JW, Dedhia RC. Sedative choice in drug-induced sleep endoscopy: A neuropharmacology-based review. Laryngoscope. 2017 Jan;127(1):273-279. doi: 10.1002/lary.26132. Epub 2016 Jul 1. Review.</citation>
    <PMID>27363604</PMID>
  </reference>
  <reference>
    <citation>Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.</citation>
    <PMID>26238576</PMID>
  </reference>
  <reference>
    <citation>Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16.</citation>
    <PMID>27542303</PMID>
  </reference>
  <reference>
    <citation>Thal DR, Walter J, Saido TC, Fändrich M. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol. 2015 Feb;129(2):167-82. doi: 10.1007/s00401-014-1375-y. Epub 2014 Dec 23. Review.</citation>
    <PMID>25534025</PMID>
  </reference>
  <reference>
    <citation>Whittington RA, Bretteville A, Dickler MF, Planel E. Anesthesia and tau pathology. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:147-55. doi: 10.1016/j.pnpbp.2013.03.004. Epub 2013 Mar 25. Review.</citation>
    <PMID>23535147</PMID>
  </reference>
  <reference>
    <citation>Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science. 2013 Oct 18;342(6156):373-7. doi: 10.1126/science.1241224.</citation>
    <PMID>24136970</PMID>
  </reference>
  <reference>
    <citation>Svetoni F, Frisone P, Paronetto MP. Role of FET proteins in neurodegenerative disorders. RNA Biol. 2016 Nov;13(11):1089-1102. Epub 2016 Jul 14. Review.</citation>
    <PMID>27415968</PMID>
  </reference>
  <reference>
    <citation>Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006 Sep;26(9):1198-212. Epub 2006 Jan 18.</citation>
    <PMID>16421508</PMID>
  </reference>
  <reference>
    <citation>Kotagal V, Bohnen NI, Müller ML, Frey KA, Albin RL. Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease. J Parkinsons Dis. 2017;7(1):143-147. doi: 10.3233/JPD-160985.</citation>
    <PMID>28106566</PMID>
  </reference>
  <reference>
    <citation>Shah N, Frey KA, Müller ML, Petrou M, Kotagal V, Koeppe RA, Scott PJ, Albin RL, Bohnen NI. Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease. Mov Disord. 2016 Jan;31(1):111-7. doi: 10.1002/mds.26369. Epub 2015 Sep 18.</citation>
    <PMID>26380951</PMID>
  </reference>
  <reference>
    <citation>Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014 Jun;71(6):758-66. doi: 10.1001/jamaneurol.2014.290. Erratum in: JAMA Neurol. 2014 Jun;71(6):803.</citation>
    <PMID>24756323</PMID>
  </reference>
  <reference>
    <citation>Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology. 2012 Sep 11;79(11):1161-7. doi: 10.1212/WNL.0b013e3182698d4a. Epub 2012 Aug 29.</citation>
    <PMID>22933741</PMID>
  </reference>
  <reference>
    <citation>Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1331-8. doi: 10.1136/jnnp.2007.127878. Epub 2008 Jul 24.</citation>
    <PMID>18653550</PMID>
  </reference>
  <reference>
    <citation>Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008 Sep 16;71(12):903-10. doi: 10.1212/01.wnl.0000326146.60732.d6.</citation>
    <PMID>18794492</PMID>
  </reference>
  <reference>
    <citation>Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010 Jan 5;74(1):77-84. doi: 10.1212/WNL.0b013e3181c7da8e.</citation>
    <PMID>20038776</PMID>
  </reference>
  <reference>
    <citation>Ito H, Shinotoh H, Shimada H, Miyoshi M, Yanai K, Okamura N, Takano H, Takahashi H, Arakawa R, Kodaka F, Ono M, Eguchi Y, Higuchi M, Fukumura T, Suhara T. Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):745-54.</citation>
    <PMID>24233004</PMID>
  </reference>
  <reference>
    <citation>Sivanesam K, Andersen NH. Modulating the Amyloidogenesis of α-Synuclein. Curr Neuropharmacol. 2016;14(3):226-37. Review.</citation>
    <PMID>26517049</PMID>
  </reference>
  <reference>
    <citation>Terrelonge M Jr, Marder KS, Weintraub D, Alcalay RN. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. J Mol Neurosci. 2016 Jan;58(1):88-92. doi: 10.1007/s12031-015-0647-x. Epub 2015 Sep 2.</citation>
    <PMID>26330275</PMID>
  </reference>
  <reference>
    <citation>Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.</citation>
    <PMID>25971633</PMID>
  </reference>
  <reference>
    <citation>Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller ML, Albin RL, Frey KA. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord. 2015 Jun;30(7):928-35. doi: 10.1002/mds.26191. Epub 2015 Apr 16. Review.</citation>
    <PMID>25879534</PMID>
  </reference>
  <reference>
    <citation>Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3. Epub 2015 Mar 11.</citation>
    <PMID>25758940</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

